SGLT2 inhibitors - a breakthrough in treatment of heart failure and their multipotential beneficial role in cardiology, diabetology, nephrology and neurology

Inhibitors of the sodium-glucose cotransporter 2 (SGLT2 inhibitors) are relatively new andinnovative antihyperglycemic drugs which by inhibiting sodium-glucose cotransporter 2 minimalisereabsorption of glucose in nephrones. Due to this process, SGLT2 inhibitors became a first-choicedrugs in diabetology. Flozins were a turning point in many clinical trials and currently consequentlyconquer pharmacoterapy in cardiology. In the past years, clinical studies proved vast role of SGLT2inhibitors in other fields of medicine. Flosins protect heart muscle and kidneys among patients with orwithout type diabetes mellitus type 2. They have positive effect on hypertension, arteries and braintissue.Cardiological condition with the lowest long-term outcome in patients is heart failure with reducedejection fraction. Until flozins, treatment in heart failure with reduced ejection fraction was based onfour groups of drugs: β-blocker, inhibitors of the renin-angiotensin aldosterone system (RAA),including angiotensin converting enzyme ACE/ARB inhibitors, angiotensin and neprilysin receptorblockers (ARNI) and mineralocorticoid receptor antagonists (MRA). It was an appropriate HFrEFtreatment over the last years. However thanks to large-scale researches a role of flozins in cardiologyhave been established and they became hope for a change in the course of heart failure.The following article presents aspects of using flozins in treatment of patients with HFrEF,multipotential usage, vast benefits for patients, not solely cardiologic, and side effects of thesemiraculous group of drugs.